210 related articles for article (PubMed ID: 31264832)
1. Activity-Guided Design of HDAC11-Specific Inhibitors.
Son SI; Cao J; Zhu CL; Miller SP; Lin H
ACS Chem Biol; 2019 Jul; 14(7):1393-1397. PubMed ID: 31264832
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase 11 Is an ε-N-Myristoyllysine Hydrolase.
Moreno-Yruela C; Galleano I; Madsen AS; Olsen CA
Cell Chem Biol; 2018 Jul; 25(7):849-856.e8. PubMed ID: 29731425
[TBL] [Abstract][Full Text] [Related]
3. HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2.
Cao J; Sun L; Aramsangtienchai P; Spiegelman NA; Zhang X; Huang W; Seto E; Lin H
Proc Natl Acad Sci U S A; 2019 Mar; 116(12):5487-5492. PubMed ID: 30819897
[TBL] [Abstract][Full Text] [Related]
4. Garcinol Is an HDAC11 Inhibitor.
Son SI; Su D; Ho TT; Lin H
ACS Chem Biol; 2020 Nov; 15(11):2866-2871. PubMed ID: 33034447
[TBL] [Abstract][Full Text] [Related]
5. Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
Tian Y; Lv W; Li X; Wang C; Wang D; Wang PG; Jin J; Shen J
Bioorg Med Chem Lett; 2017 Jul; 27(13):2943-2945. PubMed ID: 28501514
[TBL] [Abstract][Full Text] [Related]
6. Medicinal chemistry updates of novel HDACs inhibitors (2020 to present).
He X; Hui Z; Xu L; Bai R; Gao Y; Wang Z; Xie T; Ye XY
Eur J Med Chem; 2022 Jan; 227():113946. PubMed ID: 34775332
[TBL] [Abstract][Full Text] [Related]
7. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
Luo Y; Li H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylases: structural determinants of inhibitor selectivity.
Micelli C; Rastelli G
Drug Discov Today; 2015 Jun; 20(6):718-35. PubMed ID: 25687212
[TBL] [Abstract][Full Text] [Related]
10. From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
Qiu X; Zhu L; Wang H; Tan Y; Yang Z; Yang L; Wan L
Bioorg Med Chem; 2021 Dec; 52():116510. PubMed ID: 34826681
[TBL] [Abstract][Full Text] [Related]
11. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
Eom GH; Kook H
Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
13. An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives.
Su M; Gong X; Liu F
Expert Opin Drug Discov; 2021 Jul; 16(7):745-761. PubMed ID: 33530771
[TBL] [Abstract][Full Text] [Related]
14. HDAC11 is a novel drug target in carcinomas.
Deubzer HE; Schier MC; Oehme I; Lodrini M; Haendler B; Sommer A; Witt O
Int J Cancer; 2013 May; 132(9):2200-8. PubMed ID: 23024001
[TBL] [Abstract][Full Text] [Related]
15. Towards isozyme-selective HDAC inhibitors for interrogating disease.
Gupta P; Reid RC; Iyer A; Sweet MJ; Fairlie DP
Curr Top Med Chem; 2012; 12(14):1479-99. PubMed ID: 22827519
[TBL] [Abstract][Full Text] [Related]
16. Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach.
Hsu KC; Liu CY; Lin TE; Hsieh JH; Sung TY; Tseng HJ; Yang JM; Huang WJ
Sci Rep; 2017 Jun; 7(1):3228. PubMed ID: 28607401
[TBL] [Abstract][Full Text] [Related]
17. Profiling technologies for the identification and characterization of small-molecule histone deacetylase inhibitors.
Liao D
Drug Discov Today Technol; 2015 Nov; 18():24-8. PubMed ID: 26723889
[TBL] [Abstract][Full Text] [Related]
18. Unraveling HDAC11: Epigenetic orchestra in different diseases and structural insights for inhibitor design.
Khatun S; Prasad Bhagat R; Dutta R; Datta A; Jaiswal A; Halder S; Jha T; Amin SA; Gayen S
Biochem Pharmacol; 2024 Jul; 225():116312. PubMed ID: 38788962
[TBL] [Abstract][Full Text] [Related]
19. Design of selective histone deacetylase inhibitors: rethinking classical pharmacophore.
Melesina J; Praetorius L; Simoben CV; Robaa D; Sippl W
Future Med Chem; 2018 Jul; 10(13):1537-1540. PubMed ID: 29966452
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
Chen C; Hou X; Wang G; Pan W; Yang X; Zhang Y; Fang H
Eur J Med Chem; 2017 Jun; 133():11-23. PubMed ID: 28371677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
